CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Travere Therapeutics Inc   (TVTX)
Other Ticker:  
 
 

TVTX's Revenue Growth by Quarter and Year

Travere Therapeutics Inc 's Revenue results by quarter and year




TVTX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 55.87 57.25 51.14
III Quarter September 37.10 53.50 68.22 48.43
II Quarter June 59.70 54.17 54.62 47.77
I Quarter March 56.99 48.49 47.41 46.69
FY   153.79 212.03 227.50 194.03



TVTX Revenue third quarter 2023 Y/Y Growth Comment
Travere Therapeutics Inc reported fall in Revenue in the third quarter 2023 by -30.66% to $ 37.10 millions, from the same quarter in 2022.
The drop in the third quarter 2023 Travere Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 22.31%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Revenue growth. While Travere Therapeutics Inc ' s Revenue drop of -30.66% ranks overall at the positon no. 1429 in the third quarter 2023.


TVTX Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December - -2.41 % 11.95 % 15.26 %
III Quarter September -30.66 % -21.58 % 40.86 % 8.32 %
II Quarter June 10.21 % -0.82 % 14.34 % 20.72 %
I Quarter March 17.53 % 2.28 % 1.54 % 6.67 %
FY   - -6.8 % 17.25 % 12.53 %

Financial Statements
Travere Therapeutics Inc 's third quarter 2023 Revenue $ 37.10 millions TVTX's Income Statement
Travere Therapeutics Inc 's third quarter 2022 Revenue $ 53.50 millions Quarterly TVTX's Income Statement
New: More TVTX's historic Revenue Growth >>


TVTX Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December - 4.43 % -16.08 % 5.6 %
III Quarter September -37.86 % -1.24 % 24.9 % 1.38 %
II Quarter June 4.76 % 11.71 % 15.21 % 2.31 %
I Quarter March 2 % -15.3 % -7.29 % 5.23 %
FY (Year on Year)   - -6.8 % 17.25 % 12.53 %


Explore TVTX Customer Growth by Product and Service >> Back to TVTX Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #201
Overall #1429

Revenue Y/Y Growth Statistics
High Average Low
254.19 % 22.31 % -6.8 %
(Dec. 30, 2015)  
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #201
Overall #1429
Revenue Y/Y Growth Statistics
High Average Low
254.19 % 22.31 % -6.8 %
(Dec. 30, 2015)  

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Travere Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
20479.69 % 609.25 % -37.86 %
(Jun 30 2014)  


TVTX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Travere Therapeutics Inc disclosed fall in Revenue sequentially by -37.86% to $ 37.10 millions, from $ 59.70 millions declared in the previous reporting period.

As we evaluate current slump at the III. Quarter, we must assume, that usually III. Quarter performance occur sluggish relative to the preciding period

Within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Revenue quarter on quarter growth. While Travere Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1908.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #251
Overall #1908
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #251
Overall #1908
Revenue Q/Q Growth Statistics
High Average Low
20479.69 % 609.25 % -37.86 %
(Jun 30 2014)  


TVTX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Travere Therapeutics Inc disclosed fall in Revenue from the previous quarter by -37.86% to $ 37.10 millions, from $ 59.70 millions released in the previous reporting period.

It's not big concern, as Travere Therapeutics Inc 's Revenue always tend to dip in the III. Quarter.

Within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Revenue quarter on quarter growth. While Travere Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1908.


Travere Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 209.65 $ 226.05 $ 220.52 $ 212.02 $ 213.40
Y / Y Revenue Growth (TTM) -1.76 % -0.91 % -3.52 % -6.8 % -3.61 %
Year on Year Revenue Growth Overall Ranking # 1354 # 1173 # 1068 # 860 # 461
Seqeuential Revenue Change (TTM) -7.26 % 2.51 % 4.01 % -0.65 % -6.45 %
Seq. Revenue Growth (TTM) Overall Ranking # 2466 # 2170 # 2213 # 2547 # 511

New: More TVTX's historic Revenue Growth >>



Cumulative Revenue growth Comment
Travere Therapeutics Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -1.76% year on year, at Sep 30 2023 compare to the -0.91% decrease at Jun 30 2023. If the Travere Therapeutics Inc 's fiscal year would end at Sep 30 2023, annual Revenue would be $210 millions.

In the Healthcare sector 190 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1173 to 1354.

Revenue TTM Q/Q Growth Statistics
High Average Low
254.19 %
22.31 %
-6.8 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 147
Healthcare Sector # 191
Overall # 1354

Revenue TTM Y/Y Growth Statistics
High Average Low
254.19 %
22.31 %
-6.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 147
Sector # 402
S&P 500 # 2466
Cumulative Revenue growth Comment
Travere Therapeutics Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -1.76% year on year, at Sep 30 2023 compare to the -0.91% decrease at Jun 30 2023. If the Travere Therapeutics Inc 's fiscal year would end at Sep 30 2023, annual Revenue would be $210 millions.

In the Healthcare sector 190 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1173 to 1354.

Revenue TTM Q/Q Growth Statistics
High Average Low
254.19 %
22.31 %
-6.8 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 147
Healthcare Sector # 191
Overall # 1354

Revenue TTM Y/Y Growth Statistics
High Average Low
254.19 %
22.31 %
-6.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 147
Sector # 402
S&P 500 # 2466




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TVTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for TVTX's Competitors
Revenue Growth for Travere Therapeutics Inc 's Suppliers
Revenue Growth for TVTX's Customers

You may also want to know
TVTX's Annual Growth Rates TVTX's Profitability Ratios TVTX's Asset Turnover Ratio TVTX's Dividend Growth
TVTX's Roe TVTX's Valuation Ratios TVTX's Financial Strength Ratios TVTX's Dividend Payout Ratio
TVTX's Roa TVTX's Inventory Turnover Ratio TVTX's Growth Rates TVTX's Dividend Comparisons



Companies with similar Revenue decrease for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions
Viatris Inc -3.34%$ -3.342 millions
3m Company-3.56%$ -3.562 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com